Redefining multiple myeloma treatment: Advances, challenges, and future directions in immunotherapy.
10.1097/CM9.0000000000003655
- Author:
Chengcheng FU
1
;
Yingying ZHAI
1
;
Lingzhi YAN
1
;
Song JIN
1
;
Jingjing SHANG
1
;
Xiaolan SHI
1
;
Depei WU
1
Author Information
1. National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215000, China.
- Publication Type:Journal Article
- Keywords:
B cell maturation antigen;
Bispecific T cell engagers;
Chimeric antigen receptor T;
Immunotherapy;
Minimal residual disease;
Multiple myeloma
- From:
Chinese Medical Journal
2025;138(19):2399-2410
- CountryChina
- Language:English
-
Abstract:
Multiple myeloma (MM) is a hematological malignancy that poses significant treatment challenges due to its heterogeneity and propensity for relapse and progression. In the last two decades, the therapeutic landscape of MM has changed dramatically, but the disease remains largely incurable, with many patients facing treatment resistance. This review evaluates the current status of MM treatments, emphasizing the limitations of traditional therapies and the emerging role of immunotherapy in improving patient outcomes. It highlights the importance of achieving and maintaining minimal residual disease negativity and a balanced immune response as key treatment goals. Furthermore, it discusses the advancements in immunotherapies that are improving the prospects for patients, particularly those with relapsed or refractory disease. Innovative strategies, such as chimeric antigen receptor T-cell therapy, bispecific antibodies, and bispecific T cell engagers, have shown significant promise by targeting the malignant cells and the bone marrow microenvironment, which are essential for disease persistence and resistance to therapy. Future research should focus on refining MM treatment strategies, including the integration of immunotherapy into earlier treatment lines and the development of predictive biomarkers for personalized treatment approaches, ultimately enhancing patient outcomes.
